S
Sonavex
Sonavex's EchoSure detects blood clots prior to catastrophic and expensive surgical failures
About Sonavex
Sonavex is a medical technology company specializing in ultrasound-based vascular monitoring solutions. The company operates in the healthcare market, primarily serving hospitals, clinics, and surgical centers. Sonavex's core products, EchoMark and EchoSure, are designed to simplify and enhance the process of blood flow monitoring. EchoMark is the first-ever ultrasound marker for blood vessels, while EchoSure automatically detects flow loss using ultrasound technology. These innovations allow non-expert users to perform real-time, definitive, visual, and quantitative blood flow monitoring, which traditionally required expert sonographers.
Sonavex's business model revolves around the sale and limited release of its commercial products, supported by recent financing. The company generates revenue through the direct sale of its devices to healthcare providers and potentially through partnerships and collaborations within the medical field.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Baltimore, United States
- Employees
- 25
- Open positions
- None listed
- Dealroom signal
- 75.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Core AI, Spinout, AI Applications, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech, Computer Vision
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Oct 2024 | $15M | $60M | Unorthodox ventures · JStar Holdings · Partners Investment · Riptide Ventures | ↗ |
| GRANTOther financing | May 2022 | $1.7M | — | National Institutes of Health | ↗ |
Growth signals
Latest recorded traffic for Sonavex is 1.6K monthly website visits, down 27.3% over the last three months. Sonavex's team grew 4.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
US National Science Foundation
A-Level Capital
National Institutes of Health
Series A11 investors entered at this stage
- GPGrey Sky Venture Partners
Abell Foundation
TEDCO
CRCM Ventures
Dingman Center Angels
Unorthodox ventures
JStar Holdings
Partners Investment
Riptide Ventures- OVOakwood Circle Ventures
- GCGenHenn Capital
Other known investors13 additional known investors
Johns Hopkins University
BioHealth Innovation
BlueJay Syndicate
FundRx
Johns Hopkins Technology Ventures
Keiretsu Forum
Lu Zhang
Maryland Industrial Partnerships- PGPaul Grossinger
- PGPaul Grossinger
SoGal Ventures
TMC Venture Fund
Venture for America
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sonavex on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sonavex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.